STOCK MARKET BSE NSE

Hyderabad-based Optimus Pharma gets nod from DGCI to make COVID-19 drug 'Favicovid'

Every patient must be informed and should sign a consent form before initiation of treatment, a statement from Optimus Pharma said.

Published: 24th July 2020 09:32 AM  |   Last Updated: 24th July 2020 09:32 AM   |  A+A-

pills, medicines

Image used for representation purpose. (Express Illustrations)

By Express News Service

HYDERABAD: Hyderabad-based Optimus Pharma Pvt. Ltd. received approval from the Drugs Controller General of India (DCGI) to manufacture the active pharmaceutical ingredient, Favipiravir, through its subsidiary, Optrix Laboratories, and manufacture and market its antiviral drug, Favipiravir tablets, for the treatment of patients with mild to moderate symptoms.

Every patient must be informed and should sign a consent form before initiation of treatment, a statement from Optimus Pharma said.

The tablet, ‘Favicovid,’ is a prescription-based medication and would be available through both hospitals and the retail channel.



Comments

Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the newindianexpress.com editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on newindianexpress.com are those of the comment writers alone. They do not represent the views or opinions of newindianexpress.com or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. newindianexpress.com reserves the right to take any or all comments down at any time.

flipboard facebook twitter whatsapp